INFECTIOUS DISEASES AND THEIR PREVENTION ACROSS THE SEVEN AGES OF MAN
https://doi.org/10.15690/pf.v9i6.510
Abstract
This paper will describe some important infectious diseases and their prevention, to illustrate the interconnectedness of people at different ages. The diseases of interest are congenital infections, bacterial meningitis, rotavirus and human papillomavirus, healthcare associated infections, and influenza. Vaccination of individuals in one age group, for example children, may confer benefits on adults and vice versa. Of particular interest is vaccination of the pregnant woman, especially with regards to pertussis and influenza.
About the Authors
E. David G. McIntosh AM
Imperial College, London
United Kingdom
United Kingdom
L. S. Namazova-Baranova
Scientific Center of Children’s Health, Russian Academy of Medical Science, Moscow, Russian Federation
N.I. Pirogov Russian National Research Medical University, Moscow, Russian Federation
I.M. Sechenov First Moscow State Medical University, Russian Federation
Russian Federation
Russian Federation
References
1. Lancaster P. A. 1996. URL: http://www.adb.anu.edu.au/biography/gregg-sir-norman-mcalister-10362
2. Gregg N. M. Congenital cataract following German measles in the mother. Transactions of the Ophthalmological Society of Australia. 1941; 3: 35–46.
3. Lambert S. R. Congenital rubella: the end is in sight. British Journal of Ophthalmology. 2007; 91 (11): 1418–1419.
4. WHO 2012a: http://www.who.int/immunization/newsroom/Measles_Rubella_StrategicPlan_2012_2020.pdf
5. Harris J. W. Influenza occurring in pregnant women. JAMA. 1919; 72: 978.
6. Mosby L. G., Rasmussen S. A., Jamieson D. J. 2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature. Am J Obstet Gynecol. 2011; 205: 10.
7. JCVI 2010: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@ab/documents/digitalasset/dh_121763.pdf
8. WHO 2012b: http://www.who.int/immunization_monitoring/diseases/neonatal_tetanus/en/index.html
9. RCOG 2010: http://www.rcog.org.uk/files/rcog-corp/Preventing%20Group%20B%20Streptococcus%20(GBS)%20Infection%20In%20Newborn%20Babies.pdf
10. CDC 2012. URL: http://www.cdc.gov/groupbstrep/about/prevention.html
11. Heath P. T., Feldman R. G. Vaccination against group B streptococcus. Expert Review of Vaccines. 2005; 4 (2): 207–218.
12. Heath P. T. An update on vaccination against group B streptococcus. Expert Review of Vaccines. 2011; 10 (5): 685–694.
13. Peltola H., Kayhty H., Sivonen A., Makela P. H. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics. 1977; 60: 730–737.
14. Ojo L. R., O’Loughlin R. E., Cohen A. L., Loo J. D., Edmond K. M., Shetty S. S., Bear A. P., Privor-Dumm L., Griffiths U. K., Hajjeh R. Global use of Haemophilus influenzae type b conjugate vaccine. Vaccine. 2010; 28: 7117–7122.
15. Pilishvili T., Lexau C., Farley M. M., Hadler J., Harrison L. H., Bennett N. K. et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. Journal of Infectious Diseases. 2010; 201: 32–41.
16. Singleton R., Wenger J., Klejka J. A., Bulkow L. R., Thompson A., Sarkozy D. et al. The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial. Pediatric Infectious Disease Journal. September 2012 (published on-line ahead of print).
17. van den Bruel A., Thompson M., Buntinx F., Mant D. Clinicians’ gut feeling about serious infections in children: observational study. British Medical Journal. 2012; 345: e6144.
18. Viner R. M., Booy R., Johnson H., Edmunds W. J., Hudson L., Bedford H., Kaczmarski E., Rajput K., Ramsay M., Christie D. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurology. 2012; 11 (9): 774–783.
19. Pace D., Pollard A. J. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012; 30S: B3–B9.
20. Dull P. M., McIntosh E. D. Meningococcal vaccine development — from glycoconjugates against MenACWY to proteins against MenB — potential for broad protection against meningococcal disease. Vaccine. 2012; 30S: B18–B25.
21. Nadel S. Prospects for eradication of meningococcal disease. Arch Dis Child. September 2012 (published on-line ahead of print).
22. Panatto D., Amicizia D., Lai P. L., Gasparini R. Neisseria meningitidis B vaccines. Expert Review of Vaccines. 2011; 10 (9): 1337–1351.
23. Adam H. J., Richardson S. E., Jamieson F. B., Rawte P., Low D. E., Fisman D. N. Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replace ment due to Hib vaccination. Vaccine. 2010; 28 (24): 4073–4078.
24. Jackson M. L., Rose C. E., Cohn A., Coronado F., Clark T. A., Wenger J. D. et al. Modeling insights into Haemophilus influenzae type b disease, transmission, and vaccine programs. Emerging Infectious Diseases. 2012; 18 (1): 13–20.
25. Isaacman D. J., Strutton D. R., Kalpas E. A., HorowiczMehler N., Stern L. S., Casciano R., Ciuryla V. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine. Clinical Therapeutics. 2008; 30 (2): 341–357.
26. Ramsay M. E., Andrews N. J., Trotter C. J., Kaczmarski E. B., Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England. British Medical Journal. 2003; 326: 365–366.
27. Stephens D. S. Protecting the herd: the remarkable effectiveness of the bacterial meningitis polysaccharide-protein conjugate vaccines in altering transmission dynamics. Transactions of the American Clinical and Climatological Association. 2011; 122: 115–123.
28. Macartney K. K., Porwal M., Dalton D., Cripps T., Maldigri T., Isaacs D., Kesson A. Decline in rotavirus hospitalisations following introduction of Australia’s national rotavirus immunization programme. J Pediatr Child Health. 2011; 47 (5): 266–270.
29. Ang L. W., Chua L. T., James L., Goh K. T. Epidemiological surveillance and control of rubella in Singapore, 1991–2007. Annals of the Academy of Medicine, Singapore. 2012; 39 (2): 95–101.
30. Tully J., Viner R. M., Coen P. G., Stuart J. M., Zambon M., Peckham C., Booth C., Klein N., Kaczmarski E., Booy R. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. British Medical Journal. 2006; 332: 445.
31. Borg J., Christie D., Coen P. G., Booy R., Viner R. M. Outcomes of meningococcal disease in adolescence: prospective, matchedcohort study. Pediatrics. 2009; 123: e502–e509.
32. Kahn J. A., Brown D. R., Ding L., Widdice L. E., Shew M. L., Glynn S., Bernstein D. I. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics. 2012; 130 (2): e249–e256.
33. Cherry J. D. Epidemic pertussis in 2012 — the resurgence of a vaccine-preventable disease. New England Journal of Medicine. August 2012 (published on-line ahead of print).
34. Department of Health. 2012. URL: http://transparency.dh.gov.uk/2012/09/28/jcvi-pertussis/
35. McConnell M. J., Dominguez-Herrera, Smani Y., Lopez-Rojas R., Docobo-Perez F., Pachon J. Vaccination with outer membrane complexes elicits rapid protective immunity to multidrugresistant Acinetobacter baumannii. Infetion and Immunity. 2011; 79 (1): 518–526.
36. Lindsay J. A., Holden M. T. Understanding the rise of the superbug: investigation of the evolution and genomic variation of Staphylococcus aureus. Funct Integr Genomics. 2006; 6: 186–201.
37. Ragle B. E., Karginov V. A., Wardenburg J. B. Prevention and treatment of Staphylococcus aureus pneumonia with a -cyclodextrin derivative. Antimicrob Agents Chemother. 2010; 54 (1): 298–304.
38. Kaslow D. C., Shiver J. W. Clostridium difficile and methicillinresistant Staphylococcus aureus: emerging concepts in vaccine development. Annual Review of Medicine. 2011; 62: 201–215.
39. Gardiner D. F., Rosenberg T., Zaharatos J., franco D., Ho D. D. A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine. 2009; 27 (27): 3598–3604.
40. Karpova L. S., Popovtseva N. M., Stolyarova T. P., Stolyrov K. A., Mamadialiyev S. M., Khairullin B. M. et al. Comparison of influenza outbreaks in the Republic of Kazakhstan and Russia induced by 2009 yearly new variant A (H1N1) virus. Virologica Sinica. 2011a; 26 (5): 306–314.
41. Karpova L. S., Marinich I. G., Popovtseva N. M., Stoliarova T. P. Epidemiology of influenza A (H1N1) in population of 49 cities in Russia in 2009–2010. Zhurnal Mikrobiologii, Epidemiologii Immunobiologii. 2011; 3: 14–20.
42. Reichert T. A., Sugaya N., Fedson D. S., Glezen W. P., Simonsen L., Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med. 2001; 344 (12): 889–896.
43. Sugaya N., Takeuchi Y. Mass vaccination of schoolchildren against influenza and its impact on the influenza-associated mortality rate among children in Japan. Clin Infect Dis. 2005; 41 (7): 939–947.
44. Piedra P. A., Gaglani M. J., Kozinetz C. A., Herschler G., Riggs M., Griffith M. et al. Herd immunity in adults against influenzarelated illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine. 2005; 23 (13): 1540–1548.
45. Healy C. M., Baker C. J. Maternal immunization. Pediatric Infectious Disease Journal. 2007; 26: 945–948.
46. Omer S. B., Goodman D., Steinhoff M. C., Rochat R., Klugman K. P., Stoll B. J., Ramakrishnan U. Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study. PLoS Med. 2011; 8: e1000441.
Review
For citations:
G. McIntosh AM E., Namazova-Baranova L.S. INFECTIOUS DISEASES AND THEIR PREVENTION ACROSS THE SEVEN AGES OF MAN. Pediatric pharmacology. 2012;9(6):6-8. (In Russ.) https://doi.org/10.15690/pf.v9i6.510
Views:
774
Email this article 